Key result
The ORION-A trial is an ongoing open-label randomized study designed to evaluate whether adding oral acetazolamide to standard therapy improves compensation in patients with decompensated heart failure.
Why the study?
The study was designed to evaluate the efficacy and safety of oral acetazolamide compared with standard therapy in patients hospitalized with decompensated heart failure within 72 hours from admission.
Does oral acetazolamide added to standard therapy improve clinical compensation in patients with NYHA class II-IV decompensated heart failure?
RCT (n=400)
Open-label
Block randomization
Yes
Does oral acetazolamide added to standard therapy improve clinical compensation in patients with NYHA class II-IV decompensated heart failure?
The ORION-A trial protocol describes an open-label randomized study to evaluate the efficacy and safety of oral acetazolamide added to standard therapy for achieving clinical decongestion in patients with decompensated heart failure.
No takes yet. Share an insight, caveat, or question.
This planned RCT of oral acetazolamide in decompensated HF leaves open its efficacy and safety versus standard therapy.
Рубаненко et al. (2023) conducted an RCT in Decompensated heart failure (n=400). Acetazolamide vs. Standard therapy was evaluated on Number of patients who achieved compensation in accordance with the criteria for diuretic therapy discontinuation. The ORION-A trial is an ongoing open-label randomized study designed to evaluate whether adding oral acetazolamide to standard therapy improves compensation in patients with decompensated heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: